some MOM; mLs of MOM and formula (no DHM was used) were measured daily, and MOM dose was calculated both as a percentage of total enteral feedings and as a weight-adjusted (mL/kg/day) measure. Morbidities were diagnosed and validated independently by 2 neonatologists; cost data were actuarial rather than estimated, and propensity scoring was used to control for the risk of morbidities (confounders). Data revealed a dose-response relationship between higher amounts of MOM received during critical exposure periods during the NICU hospitalization and a reduction in the risk of specific morbidities and their costs (Table 1 ). These findings suggest that MOM functions by different mechanisms over the course of critical exposure periods to reduce the risk of potentially preventable morbidities and their associated costs in VLBW infants. 
